<?xml version='1.0' encoding='UTF-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN" "JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta id="journal-meta-cf83f094b37148c59ce182eab8bf366e">
      <journal-id journal-id-type="nlm-ta">Sciresol</journal-id>
      <journal-id journal-id-type="publisher-id">Sciresol</journal-id>
      <journal-id journal-id-type="journal_submission_guidelines">https://jmsh.ac.in/</journal-id>
      <journal-title-group>
        <journal-title>Journal of Medical Sciences and Health</journal-title>
      </journal-title-group>
      <issn publication-format="print"/>
    </journal-meta>
    <article-meta id="article-meta-e22e2bb320d048f5ba4969831012b9b7">
      <article-id pub-id-type="doi">10.46347/jmsh.v9i1.22.428</article-id>
      <article-categories>
        <subj-group>
          <subject>CASE REPORT</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title id="article-title-5f502b5c32604de68bc2f0940e29550d">Myeloid Sarcoma: A Mediastinal Masquerader</article-title>
        <alt-title alt-title-type="right-running-head">Myeloid Sarcoma: A mediastinal masquerader</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name id="name-8673c945f6204d88a5aaac3fa6614fd3">
            <surname>Paul</surname>
            <given-names>Jocelyn Sara</given-names>
          </name>
          <xref id="xref-849e0e4ebb974eada53cf8cd9028553a" rid="aff-2cc3dc8275424c5d90cbb932cb6a195a" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name id="name-814786e171224253bfd86335285f1fe6">
            <surname>Gandhi</surname>
            <given-names>Jahnavi</given-names>
          </name>
          <email>drjahnavigandhi@gmail.com</email>
          <xref id="xref-91a4b2ad81f94760b83d71fd79787393" rid="aff-89f097ece4434dceae96423cf680be79" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name id="name-295d478263bb425bb9c65bd5d919d15e">
            <surname>Sawhney</surname>
            <given-names>Jyoti</given-names>
          </name>
          <xref id="xref-7b68505854c545e8a96af98f56d6b27b" rid="aff-6c1d5801ca9844548ab401d3b94f1c84" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name id="name-79ba865e19c444e2b5a9c17f5c669ec8">
            <surname>Patel</surname>
            <given-names>Trupti</given-names>
          </name>
          <xref id="xref-e2826c394781487194490104db340ea7" rid="aff-2d66e7c6ae5d4ac99481ccb22d7c8def" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name id="name-f30cad09946e40e3b7c7e56f89b23d52">
            <surname>Trivedi</surname>
            <given-names>Priti</given-names>
          </name>
          <xref id="xref-8bb84f06faa64b0c898a0e8ead713346" rid="aff-89cf9259794640628172b4b00d8db270" ref-type="aff">5</xref>
        </contrib>
        <aff id="aff-2cc3dc8275424c5d90cbb932cb6a195a">
          <institution>Oncopathology Resident, Department of Oncopathology, The Gujarat Cancer and Research Institute</institution>
          <addr-line>Gujarat</addr-line>
          <country country="IN">India</country>
        </aff>
        <aff id="aff-89f097ece4434dceae96423cf680be79">
          <institution>Assistant Professor in Pathology, Department of Oncopathology, The Gujarat Cancer and Research Institute</institution>
          <addr-line>Gujarat</addr-line>
          <country country="IN">India</country>
        </aff>
        <aff id="aff-6c1d5801ca9844548ab401d3b94f1c84">
          <institution>Assistant Professor in Pathology, Department of Oncopathology, The Gujarat Cancer and Research Institute</institution>
          <addr-line>Gujarat</addr-line>
          <country country="IN">India</country>
        </aff>
        <aff id="aff-2d66e7c6ae5d4ac99481ccb22d7c8def">
          <institution>Associate Professor in Pathology, Department of Oncopathology, Associate Professor in Pathology, The Gujarat Cancer and Research Institute</institution>
          <addr-line>Gujarat</addr-line>
          <country country="IN">India</country>
        </aff>
        <aff id="aff-89cf9259794640628172b4b00d8db270">
          <institution>Head of the Department of Oncopathology, The Gujarat Cancer and Research Institute</institution>
          <addr-line>Gujarat</addr-line>
          <country country="IN">India</country>
        </aff>
      </contrib-group>
      <volume>9</volume>
      <issue>1</issue>
      <fpage>121</fpage>
      <permissions>
        <copyright-year>2023</copyright-year>
      </permissions>
      <abstract id="abstract-abstract-title-d2e38bed016d4d0c8df602ed99ca0559">
        <title id="abstract-title-d2e38bed016d4d0c8df602ed99ca0559">Abstract</title>
        <p id="paragraph-3c71c4e8f520440b8f69f29b937e145b">Mediastinal Myeloid Sarcoma is a rare entity. Here we present a case of a 28-year-old gentleman, who first presented with a mediastinal mass and was clinically considered lymphoblastic lymphoma. He was diagnosed initially as having T lymphoblastic lymphoma on a mediastinal trucut biopsy. After one month patient was diagnosed with Acute myeloid leukemia on peripheral smear and bone marrow examination and was confirmed with the help of flow cytometry. The biopsy slides from the mediastinal mass were reviewed and based on the smear findings additional immunohistochemical markers were added and diagnosed as Myeloid Sarcoma.</p>
        <p id="p-e8e2afb9ef56"/>
      </abstract>
      <kwd-group id="kwd-group-ef2b4eb7b5fc4acf87ceb32ac1a3879e">
        <title>Keywords</title>
        <kwd>Myeloid sarcoma</kwd>
        <kwd>Mediastinum</kwd>
        <kwd>Acute myeloid leukemia</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title id="title-8eee68b5250a4e2b8870139cc2168945">Introduction</title>
      <p id="paragraph-b5148a54aa634d64a462f064bc7fee61">Myeloid sarcoma (MS) is an uncommon neoplastic condition. <sup id="superscript-e525683a20a24145a21dcb827190ac1b"><xref id="xref-70855d54642744c782e8c97a8d7685a6" rid="R171273727172203" ref-type="bibr">1</xref></sup><sup id="superscript-f7a4d8f86b6a495da8a12061e0354316"> </sup>It consists of immature myeloid cells occurring at an extramedullary site like the bone, skin, or lymph node, although any part of the body may be affected. <sup id="superscript-476053728892497eb62db1eb50475b40"><xref id="xref-a833c3c0fcfc4185ab513fe74c37b654" rid="R171273727172203" ref-type="bibr">1</xref></sup> Primary mediastinal myeloid sarcoma can be misdiagnosed as lymphoma if this differential is not kept in mind. The age-adjusted incidence rate of isolated MS is 0.9% with a median age of 59 years. <sup id="superscript-b25f44a1308a4887a79d7f5240f94546"><xref id="xref-fc90fed773854c728b5be464b39218cb" rid="R171273727172208" ref-type="bibr">2</xref></sup> Isolated myeloid sarcoma (MS) is an extramedullary tumor mass composed of malignant myeloid precursor cells without any evidence of leukemic cells in the peripheral blood and bone marrow.<xref id="xref-8356a3972192411fbbde700b4a1bfab2" rid="R171273727172202" ref-type="bibr">3</xref> The incidence of mediastinal myeloid sarcoma was around 0.03%. <sup id="superscript-a733779eb98a489aa89970414aea564e"><xref id="xref-9bbd05ce45e44c77bab3235b176d2e44" rid="R171273727172204" ref-type="bibr">4</xref></sup> </p>
    </sec>
    <sec>
      <title id="t-201aaa39b0e4">Case History</title>
      <p id="paragraph-89cd4dd9c75143e8b90fb719cc94d389">A 28-year-old gentleman presented with difficulty in breathing. The laboratory investigations showed hemoglobin 11.8 gm/dl, WBC: 4500/ cumm, and platelet: 2,52,000/ cumm. No records of any peripheral smear study were available. CT scan revealed a heterogeneously enhancing multiloculated soft tissue density lesion measuring 95x66x43 mm3 in the anterior superior mediastinum. Few enlarged pretracheal and hilar nodes were seen. Moderate pericardial effusion and mild pleural effusion were present. A possibility of lymphoma was suggested in the scan report. A diagnosis of Malignant round cell neoplasm was suggested elsewhere on mediastinal biopsy. A diagnosis favoring T Lymphoblastic Lymphoma was given following immunohistochemistry. The patient was referred to our institute after one month. </p>
      <p id="paragraph-40948b2da1b04026b6db3d2e9fc88cd9">We initially received a trucut biopsy from the mediastinal mass for review. It was a suboptimal biopsy with an extensive crushing artifact. Biopsy showed a neoplasm composed of small to medium-sized cells, with scant to moderate eosinophilic cytoplasm, mild to moderately pleomorphic cells with an irregular nuclear outline, finely dispersed chromatin, and some showing nucleoli. <xref id="x-cc037e37a12d" rid="figure-2cb2b97fb1a84fb2b2acd8f7820dff0f" ref-type="fig">Figure 1</xref>) No sclerosis was noted. ﻿Histopathological diagnosis was given as ﻿small round cell tumor – mediastinal? Non-Hodgkin Lymphoma? Other round cell tumor. Immunohistochemistry was done. The panel included Terminal deoxynucleotidyl transferase (Tdt), CD 79a, CD 3, PAX 5, CD 10, AE1, Vimentin, CD99, CD 2, CD 8, CD 34, and CD 4, all of which came negative except for CD 34 (<xref id="x-b2bc41d2c830" rid="figure-e88d15eda476475f9769f4479b084fce" ref-type="fig">Figure 2</xref>) and CD 4 which was positive. MIB 1 was around 80%. Simultaneously we received peripheral blood and bone marrow sample from the same patient in the hematology department. Lab investigations showed hemoglobin 11.9 gm/dl, WBC: 9000/ cumm, and platelet: 1,20,000 / cumm. Peripheral blood had 58% blasts. Bone marrow showed around 60% blasts. Blasts were medium-sized with moderate to abundant vacuolated cytoplasm, some showing granules, round/ oval nuclei, and dispersed chromatin. (<xref id="x-d7776c567900" rid="figure-da5487513c4840299ade394e500361db" ref-type="fig">Figure 3</xref>) Special stains were done. Sudan black was positive and Periodic acid–Schiff stain (PAS) was negative. Marrow report was given as marrow involved by Acute Myeloblastic Leukemia (AML). Flow cytometry was done for confirmation. In the bone marrow sample, 64% of blasts were gated using CD 45 V 500C vs side scatter. The blasts mainly expressed myeloid markers Myeloperoxidase (MPO), CD 13, CD 33, and CD 117 along with CD 34. All T cell markers were negative (cCD 3, CD 7, sCD 3, CD 4, CD 5, CD 2, CD 8, Tdt) </p>
      <p id="paragraph-51f4d9abab5e47ff98b6029a0aae772c">Correlating with peripheral blood and marrow findings an additional panel was performed on the biopsy which included MPO (<xref id="x-e74e46d8580a" rid="figure-82167ac3d03e46bf9900c1f47666f83e" ref-type="fig">Figure 4</xref>) and CD 117 and both came as strong positive suggesting myeloid sarcoma infiltrating mediastinum. Molecular studies were also performed. FISH results which showed normal chromosome 16, negative for RUNX1-RUNX1T1 fusion, and FLT3 negative. Patient was on Daunorubicin, Vincristine, Methotrexate and Cytarabine. Post-induction marrow was in morphological remission and showed 1% blasts with an absolute neutrophil count of 2236 cells/mm3. </p>
      <fig id="figure-2cb2b97fb1a84fb2b2acd8f7820dff0f" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 1 </label>
        <caption id="caption-07519010159a4c7c8a6275288b3ba176">
          <title id="title-40c7ae7ed8ac4f478160bcc396dbf87b">
            <bold id="s-435cfe075b33">Mediastinal biopsy showing sheets of myeloblasts (x10 Hematoxylin and Eosin stain)</bold>
          </title>
        </caption>
        <graphic id="graphic-e62ed780b4a64563b3095ad55a97576d" xlink:href="https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/066f2566-143c-48e1-b8f5-97904142fd0cimage1.png"/>
      </fig>
      <fig id="figure-e88d15eda476475f9769f4479b084fce" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 2 </label>
        <caption id="caption-2dae6051262c4d28b939fbd33417b66e">
          <title id="title-84422648511b4f688df04404f679c421">
            <bold id="s-2bd2af7e7d7c">CD 34 Immunohistochemistry – Positive membranous staining (x10)</bold>
          </title>
        </caption>
        <graphic id="graphic-d824874b34bd451cba4aee6a67b70cd5" xlink:href="https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/066f2566-143c-48e1-b8f5-97904142fd0cimage2.png"/>
      </fig>
      <fig id="figure-da5487513c4840299ade394e500361db" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 3 </label>
        <caption id="caption-87b607c4a7cd4b67a5ab816bf0ea63c1">
          <title id="title-7b6d5cb0758e43eb9fc22b24ab765e7d">
            <bold id="s-c13cad2bdad8">Bone marrow aspirate smears showing myeloblasts (x100 Wright stain)</bold>
          </title>
        </caption>
        <graphic id="graphic-dee7ea7b98264368a175660ec98e92fb" xlink:href="https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/066f2566-143c-48e1-b8f5-97904142fd0cimage3.png"/>
      </fig>
      <fig id="figure-82167ac3d03e46bf9900c1f47666f83e" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 4 </label>
        <caption id="caption-03911de9429a4feeb3fd7b08424f320f">
          <title id="title-2cd290b7f63d48f6bb1661b1c5605579">
            <bold id="s-ce9ce39672f7">Myeloperoxidase (MPO) Immunohistochemistry - Positive cytoplasmic stain (x40)</bold>
          </title>
        </caption>
        <graphic id="graphic-3f26a1a3640341d29788c7fb200a946d" xlink:href="https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/066f2566-143c-48e1-b8f5-97904142fd0cimage4.png"/>
      </fig>
    </sec>
    <sec>
      <title id="title-c2981e7d4ed047fb9bbe2bba2e71c277">Discussion</title>
      <p id="paragraph-cd3cb271dbf146278f209390a343ce4b">Granulocytic sarcoma was first described by Burns in 1811. <sup id="superscript-74a587bc632b4e3fa3eb04d5ce4a48bf"><xref id="xref-df05ca54532545bcadfbf2fa5472e3ec" rid="R171273727172205" ref-type="bibr">5</xref></sup> Myeloid Sarcoma most commonly consists of myeloblasts, with or without features of promyelocytic or neutrophilic maturation, that partially or completely efface the tissue architecture. Sometimes it displays myelomonocytic or pure monoblastic morphologic features. Tumors with all three lineages or predominantly erythroid precursors or megakaryoblasts are rare. Myeloid Sarcoma may develop de novo or in association with Acute myeloid leukemia (AML), Myeloproliferative neoplasm (MPN), or Myelodysplastic syndrome (MDS). <sup id="superscript-504213aae51f4d24af7925571615b78a"><xref id="xref-77b2ff65364b4b2183a220c1a164e9f7" rid="R171273727172206" ref-type="bibr">6</xref></sup></p>
      <p id="paragraph-fb3732ad55b34f8294d40900602c614f">Myeloid sarcoma may present as the first manifestation of AML or any other hematological malignancy, preceding it for months or even years. <sup id="superscript-6d7e2620ae424ef59228ba34a5d6617a"><xref id="xref-a6659649e22c428bbd6aece26163e277" rid="R171273727172201" ref-type="bibr">7</xref></sup> In such cases, it can be confused with lymphoma as in our case. Myeloid sarcoma occurs rarely in the mediastinum and clinically it can mimic lymphoma. Even in the immunohistochemical step, they can be confused with lymphoma as both express certain common leukocyte antigens. The increased diagnostic error rate could be due to this lesion’s rarity and the low index of suspicion. <sup id="superscript-ef298d2e1bd3487fbfd2d74aafacd3dc"><xref id="xref-3a398076d175402d9d41006aa7134a4e" rid="R171273727172201" ref-type="bibr">7</xref></sup> In a study by Muss et al, the incidence of MS in AML has been reported as 3 to 8%. <sup id="superscript-4e10160789f942e19b0a6d66927b61aa"><xref id="xref-d5e63c0eacff4abc837340ad71be213f" rid="R171273727172197" ref-type="bibr">8</xref></sup> A careful morphological study in search of features of myeloid differentiation and a well-directed immunohistochemical study (anti-myeloperoxidase, anti-lysozyme, anti-CD15, anti-CD68), will eliminate the diagnosis of lymphoma. The exact diagnosis is important as the treatment is completely different in myeloid sarcoma and lymphoma. </p>
      <p id="paragraph-01657b8e8bc14c83a4cc14865a418f37">In immunohistochemistry for Myeloid Sarcoma CD68-KP1 is usually expressed followed by myeloperoxidase (MPO), CD117, CD99, CD68/PG-M1, lysozyme, CD34, terminal deoxynucleotidyl transferase (TdT), CD56, CD61/linker of activated T lymphocyte/factor VIII–related antigen, CD30, glycophorin A, and CD4. <sup id="superscript-b33f439a5c4043e5addaeac76a3f15a6"><xref id="xref-e544c64058b149a0a4f6009fe5a41219" rid="R171273727172198" ref-type="bibr">9</xref></sup> Acute Myeloid Leukemia can show clonal T-cell receptor rearrangements and/or express T-cell antigens, such as CD7 or CD4 (particularly in monocytic leukemias), all of which can create confusion while attempting to distinguish T-cell lymphoma from AML. <sup id="superscript-5f0f85b11fc240e3bb81037d8b53d518"><xref id="xref-498e776e2251467bbfb680d3d9590cea" rid="R171273727172199" ref-type="bibr">10</xref></sup> Myeloid sarcoma also exhibits aberrant antigenic markers like cytokeratins, and B- or T-cell markers. Cytogenetically, Myeloid Sarcoma has been found to occur in association with a variety of chromosomal abnormalities, in particular, t (8;21), inv (16), and an extra chromosome 8. <sup id="superscript-ef629310498646e9ad356ab2639b310f"><xref id="xref-93aff0c9d89b445b91907b560d1d1db9" rid="R171273727172200" ref-type="bibr">11</xref></sup></p>
      <p id="paragraph-736cb496efb84a198bd635a0df9ea0b5">This case report stresses the approach to the diagnosis of a mediastinal mass. With the age, size, and morphological picture, the differentials to be considered are Myeloid sarcoma, Lymphoblastic lymphoma, Primary Mediastinal large B cell lymphoma, and Hodgkin lymphoma. <sup id="superscript-42a44b785f084789ab9d1a3a5113f39c"><xref id="xref-4ac6c1390af543d5a1f8dd9d99e5e66e" rid="R171273727172207" ref-type="bibr">12</xref></sup> Lymphoblastic lymphoma will have medium-sized cells and tumor cells will be positive for CD34, Tdt, and T or B cell markers. A small fraction of lymphoblastic lymphoma can show negative Tdt. These cases should be thoroughly evaluated by correlating with clinical and blood pictures including peripheral smear and bone marrow. Primary mediastinal large B cell lymphoma has intermediate to large-sized cells with prominent sclerosis. Sclerosis was absent in our case. Tumor cells will be positive for CD 20, CD 19, CD79a, PAX 5, and CD 30. Hodgkin lymphoma shows Reed Sternberg cells and will be positive for CD 15, CD 30, MUM1, and weak PAX 5 positivity. </p>
      <p id="paragraph-7a58ff8d6e0146eda4902a22eff0a4d2">Here in our study the presence of blasts in the peripheral smear helped to clinch the diagnosis although Myeloid sarcoma doesn’t need to always present with a leukemic phase. A complete hematological workup should include a thorough peripheral smear examination, bone marrow study if necessary, and other ancillary techniques. </p>
    </sec>
    <sec>
      <title id="title-965665cdd9a2410f92f3ea892a35fb14">Conclusion</title>
      <p id="paragraph-9349dc235824436e82913cb89d52322f">Myeloid Sarcoma occurring in a young patient with a mediastinal mass, pericardial effusion, and pleural effusion is indeed rare. These features are usually observed in precursor T-lymphoblastic leukemia/lymphoma or classical Hodgkin lymphoma. Hence a high index of suspicion, a thorough study of the morphology including peripheral smear examination, selected immunohistochemistry panel and clinical correlation is required to arrive at the correct diagnosis.</p>
      <p id="p-5048a733acdc"/>
      <p id="p-64f40c0826d5"/>
      <p id="p-fc4b8e33f883"/>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R171273727172203">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magdy</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karim</surname>
              <given-names>Nagla Abdel</given-names>
            </name>
            <name>
              <surname>Gaber</surname>
              <given-names>Ola</given-names>
            </name>
            <name>
              <surname>Rahouma</surname>
              <given-names>Mohamed</given-names>
            </name>
            <name>
              <surname/>
              <given-names>Mohamed Ghareeb</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Myeloid Sarcoma</article-title>
          <source>Oncol Res Treat</source>
          <year>2019</year>
          <volume>42</volume>
          <issue>4</issue>
          <fpage>224</fpage>
          <lpage>229</lpage>
          <uri>https://doi.org/10.1159/000497210</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172208">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dores</surname>
              <given-names>Graça M</given-names>
            </name>
            <name>
              <surname>Devesa</surname>
              <given-names>Susan S</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>Rochelle E</given-names>
            </name>
            <name>
              <surname>Linet</surname>
              <given-names>Martha S</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>Lindsay M</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007</article-title>
          <source>Blood</source>
          <year>2012</year>
          <volume>119</volume>
          <issue>1</issue>
          <fpage>34</fpage>
          <lpage>43</lpage>
          <issn>0006-4971</issn>
          <publisher-name>American Society of Hematology</publisher-name>
          <uri>https://doi.org/10.1182/blood-2011-04-347872</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172202">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>Jung Yeon</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>Haerim</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>Hyunsoo</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>Ji Eun</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Yundeok</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Soo-Jeong</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Jin Seok</given-names>
            </name>
            <name>
              <surname>Hyun</surname>
              <given-names>Shin Young</given-names>
            </name>
            <name>
              <surname>Min</surname>
              <given-names>Yoo Hong</given-names>
            </name>
            <name>
              <surname>Cheong</surname>
              <given-names>June-Won</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement: a single-institution experience</article-title>
          <source>Blood Research</source>
          <year>2017</year>
          <volume>52</volume>
          <issue>3</issue>
          <fpage>184</fpage>
          <lpage>192</lpage>
          <issn>2287-979X</issn>
          <publisher-name>The Korean Society of Hematology</publisher-name>
          <uri>https://doi.org/10.5045/br.2017.52.3.184</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172204">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhao</surname>
              <given-names>Haiqiu</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Zhenkun</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>Dingming</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Weijie</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>Haizhou</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Zhenzhen</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>Jixin</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Haiqiong</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Runqing</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Yinyin</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>Qianqian</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Zhongxing</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Fei</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>Xinsheng</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>Rong</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma</article-title>
          <source>Scientific Reports</source>
          <year>2022</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>6752</fpage>
          <publisher-name>Springer Science and Business Media LLC</publisher-name>
          <uri>https://doi.org/10.1038/s41598-022-10831-7</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172205">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Rappaport</surname>
              <given-names>H</given-names>
            </name>
            <collab/>
          </person-group>
          <person-group person-group-type="editor"/>
          <source>Tumors of the hematopoietic system</source>
          <series>Atlas of tumor pathology</series>
          <publisher-loc>Washington DC</publisher-loc>
          <year>1966</year>
          <fpage>239</fpage>
          <lpage>285</lpage>
          <uri>https://books.google.co.in/books?hl=en&amp;lr=&amp;id=FyPqCxMumscC&amp;oi=fnd&amp;pg=PA9&amp;ots=5sY0SZ6nV-&amp;sig=IkxFS33i073WgXxlumovm7pH2-I&amp;redir_esc=y#v=onepage&amp;q&amp;f=false</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172206">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hancock</surname>
              <given-names>J C</given-names>
            </name>
            <name>
              <surname>Prchal</surname>
              <given-names>J T</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>J M</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Trilineage extramedullary myeloid cell tumor in myelodysplastic syndrome</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>1997</year>
          <volume>121</volume>
          <issue>5</issue>
          <fpage>520</fpage>
          <lpage>523</lpage>
          <uri>https://pubmed.ncbi.nlm.nih.gov/9167610/</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172201">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akkaya</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ozel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Karadogan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Beköz</surname>
              <given-names>Hüseyin</given-names>
            </name>
            <name>
              <surname>Karpuzoğlu</surname>
              <given-names>Gülten</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Mediastinal granulocytic sarcoma</article-title>
          <source>Turkish Journal of Pathology</source>
          <year>2008</year>
          <volume>24</volume>
          <issue>3</issue>
          <fpage>183</fpage>
          <lpage>185</lpage>
          <uri>https://www.turkjpath.org/text.php3?id=642</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172197">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muss</surname>
              <given-names>Hyman B</given-names>
            </name>
            <name>
              <surname>Moloney</surname>
              <given-names>William C</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Chloroma and Other Myeloblastic Tumors</article-title>
          <source>Blood</source>
          <year>1973</year>
          <volume>42</volume>
          <issue>5</issue>
          <fpage>721</fpage>
          <lpage>728</lpage>
          <issn>0006-4971</issn>
          <publisher-name>American Society of Hematology</publisher-name>
          <uri>https://doi.org/10.1182/blood.V42.5.721.721</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172198">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campidelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Agostinelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stitson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>Stefano A</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Myeloid sarcoma: extramedullary manifestation of myeloid disorders</article-title>
          <source>American journal of clinical pathology</source>
          <year>2009</year>
          <volume>132</volume>
          <issue>3</issue>
          <fpage>426</fpage>
          <lpage>437</lpage>
          <uri>https://doi.org/10.1309/ajcp1za7hyzkazhs</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172199">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewis</surname>
              <given-names>Robert E</given-names>
            </name>
            <name>
              <surname>Cruse</surname>
              <given-names>Julius M</given-names>
            </name>
            <name>
              <surname>Sanders</surname>
              <given-names>Catherine M</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>Rachel N</given-names>
            </name>
            <name>
              <surname>Suggs</surname>
              <given-names>Jeanann L</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Aberrant expression of T-cell markers in acute myeloid leukemia</article-title>
          <source>Experimental and Molecular Pathology</source>
          <year>2007</year>
          <volume>83</volume>
          <issue>3</issue>
          <fpage>462</fpage>
          <lpage>463</lpage>
          <issn>0014-4800</issn>
          <publisher-name>Elsevier BV</publisher-name>
          <uri>https://doi.org/10.1016/j.yexmp.2007.08.010</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172200">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deeb</surname>
              <given-names>George</given-names>
            </name>
            <name>
              <surname>Baer</surname>
              <given-names>Maria R</given-names>
            </name>
            <name>
              <surname>Gaile</surname>
              <given-names>Daniel P</given-names>
            </name>
            <name>
              <surname>Sait</surname>
              <given-names>Sheila N Jani</given-names>
            </name>
            <name>
              <surname>Barcos</surname>
              <given-names>Maurice N</given-names>
            </name>
            <name>
              <surname>Wetzler</surname>
              <given-names>Meir</given-names>
            </name>
            <name>
              <surname>Conroy</surname>
              <given-names>Jeffrey M</given-names>
            </name>
            <name>
              <surname>Nowak</surname>
              <given-names>Norma J</given-names>
            </name>
            <name>
              <surname>Cowell</surname>
              <given-names>John K</given-names>
            </name>
            <name>
              <surname>Cheney</surname>
              <given-names>Richard T</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Genomic profiling of myeloid sarcoma by array comparative genomic hybridization</article-title>
          <source>Genes, Chromosomes and Cancer</source>
          <year>2005</year>
          <volume>44</volume>
          <issue>4</issue>
          <fpage>373</fpage>
          <lpage>383</lpage>
          <issn>1045-2257</issn>
          <publisher-name>Wiley</publisher-name>
          <uri>https://doi.org/10.1002/gcc.20239</uri>
        </element-citation>
      </ref>
      <ref id="R171273727172207">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paydas</surname>
              <given-names>Semra</given-names>
            </name>
            <name>
              <surname>Zorludemir</surname>
              <given-names>Suzan</given-names>
            </name>
            <name>
              <surname>Ergin</surname>
              <given-names>Melek</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Granulocytic sarcoma: 32 cases and review of the literature</article-title>
          <source>Leukemia &amp; Lymphoma</source>
          <year>2006</year>
          <volume>47</volume>
          <issue>12</issue>
          <fpage>2527</fpage>
          <lpage>2541</lpage>
          <issn>1042-8194</issn>
          <publisher-name>Informa UK Limited</publisher-name>
          <uri>https://doi.org/10.1080/10428190600967196</uri>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
